Navigation Links
Fetal Heart-Cell Enzyme and Onset of Heart Failure

In almost all forms of heart failure, the heart begins to express genes that are normally only expressed in the fetal heart//. Researchers have known for years that this fetal-gene reactivation happens, yet not what regulates it. Now, investigators at the University of Pennsylvania School of Medicine have discovered that an enzyme important in fetal heart-cell development regulates the enlargement of heart cells, known as cardiac hypertrophy, which is a precursor to many forms of congestive heart failure (CHF).

The study, which paves the way for new targets for treating cardiac hypertrophy and heart failure, appears in an advanced online publication of Nature Medicine.

“It’s as if old programs are being reactivated in a sick heart,” explains senior author Jonathan A. Epstein, MD, the W.W. Smith Endowed Chair for Cardiovascular Research at Penn. “In an adult heart, stresses such as high blood pressure induce the reexpression of a fetal gene program.”

The investigators found that by inhibiting the enzyme HDAC in adult mice the fetal-gene program can be prevented from restarting. “We found that in various mouse models of cardiac hypertrophy and heart failure, treatment with chemical HDAC inhibitors or genetic deletion of HDAC2 prevented the beginning of the downward slide to progressive heart failure,” says Epstein.

HDAC is an enzyme switch that regulates how DNA is packaged inside the cell, and therefore how large groups of related genes are turned on and off. During development HDAC normally regulates proliferation of heart cells in the embryo. “This makes sense if a molecular pathway in which HDAC has a major role is re-expressed--the adult heart instead makes the cells it already has bigger since it is unable to make more cells very easily.”

The researchers also found that HDAC works in the heart in part by regulating expression of another enzyme called Inpp5f, which is involved in a pathway that contro ls the growth and multiplication of cells. Inpp5f is also related to tumor-suppressor genes involved in cancer.

“HDAC and Inpp5f give us new targets for regulating cardiac hypertrophy,” says Epstein. “Inhibitors of HDAC may warrant testing for cardiac disease to stop the hypertrophy that accompanies the re-expression of the fetal-gene program.” HDAC inhibitors are already in trials for cancer and one, valproic acid, has been used for years to treat seizures. Most CHF medications are aimed at regulating blood pressure, but very few are targeted at the heart-muscle cells themselves. About 5 million Americans are living with CHF today, according to the American Heart Association.

“To understand how to better treat heart disease at the cellular level is an important next step,” says Epstein.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Fish Found To Improve Fetal Growth
2. Fetal Cell Transplant Found To Improve Movement In Patients With Parkinson’s Disease
3. Vitamin Supplements During Pregnancy to Boost Fetal Development
4. Worried About The Sensitive Skin Of Your 2 Year Old? Fetal Skin Cells To Offer Help
5. Using Eyes As The Line Of Reference For Fetal Brain Imaging
6. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
7. Genetic Disorders, Not Fetal Distress Increase Cerebral Palsy Risk
8. Fetal Development Face The Threat By Frequent Ultrasounds
9. New Drug Could Prevent Fetal Alcohol Syndrome
10. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
11. Epilepsy Drug Poses High Risk for Fetal Death and Birth Defects
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the Founder ... as a Guest Speaker and Contributor to a weeklong series of classes, meetings, field ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an Indianapolis-based ... standard feature on its secure clinical communication platform. The platform allows clinicians to ... on the type and urgency of a situation. , “We know from ...
(Date:5/23/2017)... ... 2017 , ... Therachat , a smart guided journaling tool for improving ... current state of anxiety in support of National Mental Health Awareness Month. , The ... and benchmarked general anxiety levels as well as identified the top triggers, impact to ...
(Date:5/22/2017)... , ... May 22, 2017 , ... Today, Our Urgent ... MO with a public ribbon cutting ceremony. Since opening over a month ... alternative to the emergency room. The new Our Urgent Care walk-in clinic is ...
(Date:5/22/2017)... CA (PRWEB) , ... May 22, 2017 , ... ... will sponsor a program on Wellocity to empower WeightZone Factor members to track ... medications, and get an excellent health education, all on their mobile phones. It ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
Breaking Medicine Technology: